GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Total Assets

Evotec SE (WBO:EVT) Total Assets : €2,252.5 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Total Assets?

Evotec SE's Total Assets for the quarter that ended in Dec. 2023 was €2,252.5 Mil.

Warning Sign:

If a company builds assets at 21.8% a year, faster than its revenue growth rate of 12% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Evotec SE's average Total Assets Growth Rate was 7.10% per year. During the past 3 years, the average Total Assets Growth Rate was 19.00% per year. During the past 5 years, the average Total Assets Growth Rate was 21.80% per year. During the past 10 years, the average Total Assets Growth Rate was 34.10% per year.

During the past 13 years, Evotec SE's highest 3-Year average Total Assets Growth Rate was 62.20%. The lowest was -19.20%. And the median was 19.05%.

Total Assets is connected with ROA %. Evotec SE's annualized ROA % for the quarter that ended in Dec. 2023 was -2.86%. Total Assets is also linked to Revenue through Asset Turnover. Evotec SE's Asset Turnover for the quarter that ended in Dec. 2023 was 0.09.


Evotec SE Total Assets Historical Data

The historical data trend for Evotec SE's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Total Assets Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,180.91 1,462.34 2,235.16 2,257.25 2,252.47

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,262.66 2,257.25 2,301.22 2,254.51 2,252.47

Evotec SE Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Evotec SE's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=1119.907+1132.561
=2,252.5

Evotec SE's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=1119.907+1132.561
=2,252.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evotec SE  (WBO:EVT) Total Assets Explanation

Total Assets is connected with ROA %.

Evotec SE's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-64.524/( (2254.509+2252.468)/ 2 )
=-64.524/2253.4885
=-2.86 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Evotec SE's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=201.313/( (2254.509+2252.468)/ 2 )
=201.313/2253.4885
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Evotec SE Total Assets Related Terms

Thank you for viewing the detailed overview of Evotec SE's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines